InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, will report its third quarter 2024 financial and operating results on November 8, 2024, before the market opens. No conference call is planned.
